FDA Approves Ivosidenib for Previously Treated, IDH1-Mutated AML
The FDA approved ivosidenib, a small-molecule IDH1 inhibitor, for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and an...
Freeze-Dried Plasma Approved for Battlefield Treatment
Under an emergency-use authorization, the FDA approved the use of freeze-dried plasma by the U.S. military. The authorization, requested by the U.S. Department of...
Medical Community Reacts to the Supreme Court’s Travel Ban Ruling
On June 26, 2018, the U.S. Supreme Court voted to uphold President Donald Trump’s travel ban, restricting immigration from seven “high-risk” countries (Syria, Iran,...
FDA Issues New Guidance for Patient-Centered Drug Development
The U.S. Food and Drug Administration (FDA) recently announced an initiative to better integrate the patient experience into clinical trials. The agency has released...
Ibrutinib-Rituximab Combo Granted Priority Review
The FDA granted priority-review designation to the combination of ibrutinib and rituximab for the treatment of Waldenström macroglobulinemia (WM). The Bruton tyrosine kinase inhibitor...
Venetoclax Approved for All Patients With Relapsed/Refractory CLL and SLL
The U.S. Food and Drug Administration (FDA) granted approval to venetoclax for the treatment of patients with previously treated chronic lymphocytic leukemia (CLL) or...
AMA Announces New Approach to Physician Mental Health Care
In response to growing concerns about the mental health of physicians and medical students, the American Medical Association (AMA) has adopted a new policy...
FDA Approves Pembrolizumab for Relapsed/Refractory PMBCL
Pembrolizumab was granted an accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients with refractory...
Drug Shortages Rising Again After Five Years
For the past five years, the number of new drug shortages reported to the U.S. Food and Drug Administration (FDA) was declining steadily. However,...
FDA Opens Communication Lines Between Drug Makers and Insurers
The U.S. Food and Drug Administration (FDA) has issued final guidance documents outlining the types of information that drug companies may share with insurers,...
Current Issue
September 2018, Volume 4, Issue 11
View issue flipbook
September 2018
Volume 4, Issue 11This issue features a look at research misconduct, a debate about whether chronic lymphocytic leukemia is curable, and...
